Cyclo TherapeuticsCYTH
13F holders, Q1 2024 (March 31)22holders
1famous investor
$1.39avg. 13F price*
At the end of Q1 2024, 22 institutions reported holding Cyclo Therapeutics Inc. (CYTH) in their 13F filings. The largest holders were EPIQ Capital Group, LLC ($1.2M), Founders Fund V Management, LLC ($668K) and Vanguard Group Inc. ($551K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Cyclo Therapeutics Inc.
- CUSIP
- 23254X201
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $1.2M |
| Exits | 5 | $138K |
Ownership 22 holders
| EPIQ Capital Group, LLC | 0.47% | New | 853,815 | $1.2M |
| Founders Fund V Management, LLC | 61.13% | No change | 480,708 | $668K |
| Vanguard Group Inc. | 0.00% | Add +11.7% | 396,658 | $551K |
| Geode Capital Management, LLC | 0.00% | Add +5.0% | 159,749 | $222K |
| Founders Fund VI Management, LLC | 57.89% | No change | 110,023 | $153K |
| State Street Corp. | 0.00% | Add +0.0% | 39,530 | $55K |
| BlackRock Inc. | 0.00% | Reduce -23.4% | 37,126 | $52K |
| Northern Trust Corp. | 0.00% | Add +24.6% | 21,741 | $30K |
| Renaissance Technologies | 0.00% | New | 21,756 | $30K |
| Wealth Enhancement Advisory Services, LLC | 0.00% | Add +10.2% | 20,400 | $28K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +12.1% | 6,582 | $9K |
| UBS Group AG | 0.00% | New | 4,828 | $7K |
| Wells Fargo & Company | 0.00% | Add +91.3% | 4,565 | $6K |
| Princeton Global Asset Management LLC | 0.00% | Add +1155.3% | 3,766 | $5K |
| Morgan Stanley | 0.00% | Add +151.1% | 1,037 | $1K |
| Royal Bank of Canada | 0.00% | No change | 746 | $1K |
| JPMorgan Chase & Co. | 0.00% | Add +750.0% | 153 | $213 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 90 | $125 |
| Osaic Holdings, Inc. | 0.00% | Reduce -88.8% | 67 | $93 |
| Catalyst Funds Management Pty Ltd | 0.00% | — | 67 | $93 |
| Bank of America Corp. | 0.00% | Add +92.9% | 27 | $38 |
| Qube Research & Technologies Ltd | 0.00% | Reduce -82.6% | 21 | $29 |
"% of holder's portfolio" is CYTH's weight in each manager's 13F, not the share of Cyclo Therapeutics Inc. the manager owns.